Dr Maree Bilandzic from the Ovarian Cancer Biomarkers Research Group at Hudson Institute

Dr Maree Bilandzic

There is currently no effective treatment for ovarian cancer that achieves long-term patient survival. Dr Maree Bilandzic’s research program has a strong focus on addressing the unmet needs faced by women battling ovarian cancer: the lack of effective treatments and ways to monitor disease.

Dr Bilandzic is particularly focused on a specialised subset of ovarian cancer cells called “Leader Cells”. Leader cells are fundamental to metastasis, tumour progression and chemo resistance, yet not much is known about them in an ovarian cancer context.

Dr Bilandzic has been fortunate to receive support from philanthropic organisations such as the CASS Foundation, Fielding Foundation and the Ovarian Cancer Research Foundation. Her studies are facilitated by strong clinical collaborations within the Monash Health Translation Precinct.

Dr Bilandzic believes that understanding the molecules and pathways controlling critical stages of metastasis is essential to enable the development of treatments that specifically counter the dual problems associated with chemoresistance and tumour spread.

Selected publications

  • Moffit L, Karimnia N, Stephens AN, Bilandzic M (2019) Therapeutic Targeting of Collective Invasion in Ovarian Cancer. Int J Mol Sci in press.

  • Wilson AL, Wilson KL, Bilandzic M, Moffitt LR, Makanji M, Gorrell MD, Oehler MK, Rainczuk A, Stephens AN, Plebanski M (2018) Non-Invasive Fluorescent Monitoring of Ovarian Cancer in an Immunocompetent Mouse Model. Cancers (Basel) Dec 31;11(1). pii: E32.

  • Sandow JJ, Rainczuk A, Infusini G, Makanji M, Bilandzic M, Wilson AL, Fairweather N, Stanton PG, Garama D, Gough D, Jobling TW, Webb AI, Stephens AN (2018) Discovery and Validation of Novel Protein Biomarkers in Ovarian Cancer Patient Urine. Proteomics Clin Appl 12:e1700135. Epub 2018 Mar 2.

  • Bilandzic M, Wang Y, Ahmed N, Luwor RB, Zhu HJ, Findlay JK, Stenvers KL (2014) Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFκB-mediated induction of MMP2. Cancer Lett 354:107-114. Epub 2014 Aug 13.

  • Bilandzic M, Stenvers KL (2014) Assessment of ovarian cancer spheroid attachment and invasion of mesothelial cells in real time. J Vis Exp May 20;(87). doi: 10.3791/51655.

  • Bilandzic M, Chu S, Wang Y, Tan HL, Fuller PJ, Findlay JK, Stenvers KL (2013) Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells. Mol Endocrinol 27:466-479. Epub 2013 Jan 15.